Clinical Trial

Baseline Burden of Disease and TDM in Ulcerative Colitis

Study Description

Relationship Between Baseline Burden of Disease and TDM in Ulcerative Colitis

Ulcerative colitis (UC) is a chronic inflammatory bowel disease which often follows a relapsing/remitting course. Anti-TNF therapies are proven to be effective in UC and studies indicate that having adequate drug levels correlate with improved patient outcomes. It is unknown, however, if a high burden of disease at baseline impacts drug utilization or loss. In this study, we investigate whether measures of high burden of disease (fecal calprotectin, bowel ultrasound, and colonoscopy) at baseline predicts low drug levels after standard anti-TNF induction therapy.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Diagnostic Test - Fecal calprotectin

Stool test to look at baseline burden of inflammation

Additional Information

Official Study Title

Relationship Between Baseline Burden of Disease and Anti-TNF Drug Trough Levels in Ulcerative Colitis.

Clinical Trial ID

NCT03808506

ParticipAid ID

eXDqle